REGENOPIA – PROMISING NEW TREATMENT FOR DRY EYE DISEASE

Abstract

Dry eye syndrome is one of the main problems of modern ophthalmological pathology. Although the treatment of dry eye syndrome has made great strides, the development of new treatments continues to be a major challenge for scientists and ophthalmologists around the world. The development of highly effective and safe eye drops is especially important. The aim of the article is to conduct research on new eyedrops called Regenopia – the unique combination of three active substances: sodium hyaluronate, trehalose, and D-panthenol in the treatment of DED. Clinical observation of 128 patients (256 eyes) (85 women and 43 men 18-60 years age group with DED (patients with any chronic or autoimmune diseases were excluded from the research) treated with Regenopia was conducted from February 1-st to May 30-th, 2023. DED was diagnosed by anamnesis and instrumental clinical investigations (Visometry, Biomicroscopy, Schirmer’s test, Tear Break up time (TBUT)). Moderate dry eye - 75% (192 eyes), severe dry eye - 25% (64 eyes). In 24 eyes Superficial Punctate Keratitis (SPK) was determined after examination of the epithelial layer of the cornea and conjunctiva. One drop of Regenopia was instilled 3 times a day in both eyes by patients (in cases of SPK complex method of treatment was prescribed) and patients were called for a repeat visit in 3 weeks and 6 weeks after the start of treatment. The condition was assessed using the same methods as at the time of diagnosis. The bioprotective, osmoprotective, regenerative properties of trehalose significantly enhance hyaluronic acid’s ability to provide effective hydration and long-term symptom relief along with the regenerative action of dexpanthenol. Using Regenopia significantly reduced the intensity of symptoms, increased the patient’s ability to work, and improved the quality of life, which allows us to recommend Regenopia as an effective, safe and reliable treatment for moderate to severe dry eye disease.